first_imgRELATED ARTICLESMORE FROM AUTHOR Shannon Airport braced for a devastating blow Advertisement Housing 37 Compulsory Purchase Orders issued as council takes action on derelict sites TAGSachievementhealthLimerick City and CountyMaternity HospitalNewsUMHL Linkedin WhatsApp NewsHealthAnna is University Maternity Hospital Limerick’s first midwife sonographerBy Staff Reporter – June 18, 2019 2860 Twitter Limerick Post Show | Careers & Health Sciences Event for TY Students center_img Email Previous articlePodcast: Taking burlesque to the ‘Wild Atlantic Cabaret’ #WeAreLimerickNext articleMetal shows roll into town and Limerick has a party Staff Reporterhttp://www.limerickpost.ie Facebook Limerick on Covid watch list pictured at the University Maternity Hospital Limerick (UMHL) as it celebrated International Day of the Midwife to highlight the vital role these professionals play in the health of mothers, newborns and their families.Pic. Brian ArthurANNA Gleeson has become the first midwife-sonographer to practise at University Maternity Hospital Limerick (UMHL).Healthcare professionals providing antenatal ultrasounds have traditionally come from a radiography background but a shortage of sonographers nationally has seen practitioners start to enter through the midwifery route.Sign up for the weekly Limerick Post newsletter Sign Up Ms Gleeson has 30 years’ experience as a midwife and has recently obtained an MSc in Ultrasonography from University College Dublin. Her qualification is a positive development for women accessing maternity care in the MidWest. Anna was supported in her training and supervised by radiographer colleagues in UMHL and the Department of Radiology at University Hospital Limerick.pictured at the University Maternity Hospital Limerick (UMHL) as it celebrated International Day of the Midwife to highlight the vital role these professionals play in the health of mothers, newborns and their families.Pic. Brian Arthur“I was always interested in ultrasound and, in fact, I had done a short course on it in the UK in the past. Nothing came of that but when the opportunity came up and the hospital sought expressions of interest for a Masters in Ultrasound, I gave it serious consideration,” explained Ms Gleeson, from Kilteely, County Limerick.“When you work in a hospital, you are always going on courses to maintain and improve your skills but an 18-month commitment up to masters level is of a different order. I have five children to look after but everyone at home and at work was very supportive and I decided I would take that opportunity. It was a big commitment as it involved travelling to UCD two days every fortnight for one and half years; and a lot of study and assignments in between!”“To be honest, I was something of a matriarch in my group, which was made up of midwives and radiographers in the main. My interest, because of my background, was obviously in obstetrics and gynaecology but there were others doing the course because they wished to pursue their own interest in soft tissue or in circulation, where ultrasound also has a role.”Obstetric ultrasound services are internationally recognised as essential in providing good antenatal care. It is through ultrasound that pregnancies can be accurately dated, the gender of the baby identified and any anomalies picked up. The role of ultrasound in improving mental health in pregnancy, in providing reassurance and in strengthening the bond with baby is also recognised.Healthcare professionals who provide ultrasound imaging services need to be highly educated and highly skilled to practise and manage their caseloads in an era where pregnancies are more complex; the average age of mothers is increasing; diabetes in pregnancy is on the rise and there are more multiple births due to IVF and other factors.“The clarity of the image is vital and while the theory is all well and good, the important thing is learning a new skill so you can master the imaging techniques. A woman going in for her scan will see the sonographers making it look easy but that only comes with a lot of training; and hand-eye co-ordination is very important,” explained Ms Gleeson.These practical skills were mainly acquired locally, working with the radiographer sonographers and fetal medicine specialists in UMHL. She also spent some time in the National Maternity Hospital in Holles Street and in the Rotunda Hospital. Ms Gleeson works in both the main ultrasound department and in the Early Pregnancy Assessment Unit at UMHL. The role, she said, is very varied.“It is a special job to be there at such a happy time for women as their pregnancy is being confirmed and they themselves can see the first real pictures of their baby.  Equally, it can be a sad or difficult time especially when miscarriage is diagnosed. The way ultrasound technology has developed and improved over the years, we are more likely to pick up  deviations from the norm and, in that way, we can help mothers and their partners by referring them on to the right service and the right people, whether that be foetal medicine or cardiac services and so on. And they are therefore better prepared for follow-on care after the birth of their baby. It also helps labour ward staff plan the birth to ensure the specialties needed for the baby are present at the birth thus ensuring the best possible outcome.”Margaret Quigley, Director of Midwifery, UL Hospitals Group, commented: “We are delighted that Anna has been successful in her masters which gives her the qualification to perform prenatal ultrasounds.  She is the first midwife to work in our ultrasound department and we are very grateful for all the support she has received in the unit. We have a plan for another midwife to start the journey that Anna set out on 18 months ago and to continue to support this as a career choice into the future.” TechPost | Episode 9 | Pay with Google, WAZE – the new Google Maps? and Speak don’t Type! Print Local backlash over Aer Lingus threatlast_img read more


first_img WhatsApp AUSTIN, Texas–(BUSINESS WIRE)–Feb 19, 2021– TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin-film freeze-drying (TFFD) technology platform, today announced that, in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the Company obtained positive preclinical in vitro efficacy data from TFF formulated biodefense countermeasures. In April of 2020, TFF Pharmaceuticals and USAMRIID, part of the U.S. Army Medical Research and Development Command, the U.S. Army’s premier institution and facility for defensive research into countermeasures against biological warfare, entered into a 3-year Cooperative Research and Development Agreement (CRADA) to investigate TFFD of various biodefense countermeasures to demonstrate the use of these formulations as needle-free, inhaled treatments that are temperature-insensitive. The first two countermeasures, a monoclonal antibody (mAbs) against Ebolavirus Zaire (EBOV) and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against Venezuelan equine encephalitis virus (VEEV), were TFFD formulated and tested for efficacy in a well-established in vitro neutralization assay. Data showed that the activity of the mAbs and rVSV vaccines were preserved after TFFD. Formulation optimization and long-term stability testing are ongoing. Next steps will be in vivo testing in appropriate animal models. “This data utilizing our TFFD technology to reformulate currently developed and characterized medical countermeasures against EBOV and VEEV is an important milestone,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “Most countermeasures are parenterally delivered, require trained personnel for administration and are temperature sensitive. There is an urgent need to develop technologies to improve biodefense countermeasures to better protect the warfighter.” “Great strides have been made to develop licensed countermeasures against Department of Defense (DoD) select agents of interest, such as Ebolavirus Zaire (EBOV) and Venezuelan equine encephalitis (VEEV),” said John M. Dye, Jr., Viral Immunology branch chief, USAMRIID. “An alternate route of administration that bypasses the need for cold chain control and administration by specialized personnel could be critical in the protection of our defense forces in biologically hostile environments around the globe.” TFF continues to engage and collaborate with various government and defense contracting agencies in an effort to utilize the Company’s TFFD technology platform to formulate dry powder vaccines and therapeutics for delivery via reconstitution, or for lung or nasal inhalation. About the U.S. Army Medical Research Institute of Infectious Diseases: For over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions – vaccines, drugs, diagnostics, information, and training programs – that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency’s Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit www.usamriid.army.mil. The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred. About TFF Pharmaceuticals’ Thin Film Freezing technology platform TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent. About TFF Pharmaceuticals TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com SAFE HARBOR This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company’s TFFD platform and its dry powder versions of voriconazole and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude preclinical testing of its EBOV mAbs or rVSV vaccine or obtain pre-market approval of either product candidate, (ii) no drug product incorporating the TFFD platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFFD Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s prospectus supplement filed with the SEC on December 8, 2020. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005285/en/ CONTACT: Company: Glenn Mattes President and CEO TFF Pharmaceuticals, Inc. [email protected] 737-802-1973 Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc. [email protected] 817-989-6358 Investor Relations and Media: Paul Sagan LaVoieHealthScience [email protected] 617-953-4779 KEYWORD: TEXAS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: MEDICAL DEVICES OTHER DEFENSE INFECTIOUS DISEASES CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH DEFENSE SOURCE: TFF Pharmaceuticals, Inc. Copyright Business Wire 2021. PUB: 02/19/2021 08:30 AM/DISC: 02/19/2021 08:30 AM http://www.businesswire.com/news/home/20210219005285/en Pinterest Facebook Pinterest WhatsApp Facebook Twittercenter_img TAGS  By Digital AIM Web Support – February 19, 2021 Twitter TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Local NewsBusiness Previous articleEverbridge annuncia di essersi aggiudicata cinque contratti relativi alle soluzioni Public Warning con società di trasmissioni wireless, governi e Stati finalizzati alla protezione delle persone e delle aziende in Europa e in AsiaNext articleWilliams career-high 32 sparks WSU to romp over Cal 82-51 Digital AIM Web Supportlast_img read more


first_imgHomepage BannerNews RELATED ARTICLESMORE FROM AUTHOR By admin – December 8, 2015 Facebook Gardai continue to investigate Kilmacrennan fire Man arrested on suspicion of drugs and criminal property offences in Derry 75 positive cases of Covid confirmed in North WhatsApp Facebook Pinterest A 26 year old man, arrested in Derry  yesterday morning  in connection with the murder of Paul McCauley in the city in 2006, has been released on police bail pending further enquiries.A 26 year old man who was arrested in Coleraine this morning, in connection with the murder currently remains in custody assisting police with their enquiries. Further drop in people receiving PUP in Donegal center_img WhatsApp Previous articleCouncillor John O’Donnell issues fresh statement in light of RTE’s investigation programmeNext articleHarps sign Ryan Curran from Derry City admin 365 additional cases of Covid-19 in Republic Google+ Twitter Main Evening News, Sport and Obituaries Tuesday May 25th Pinterest One man released while one man remains in custody in connection with Paul McCauley murder Google+ Twitterlast_img read more


first_img Published on April 14, 2015 at 11:24 pm Contact Connor: [email protected] | @connorgrossman Ben Williams and Bobby Wardwell have turned in exceptional performances at the faceoff X and in goal, respectively, to lift Syracuse.But on Tuesday night in the Carrier Dome regular-season finale, two of SU’s biggest playmakers took a back seat as head coach John Desko utilized his team’s depth more than he had all season.It was third-year midfielder Cal Paduda at the X who succeeded in his biggest dose of playing time all year going against Hobart.“It was important for us, especially in Cal’s case to get him out there,” Desko said. “He’s been doing a great job in practice and he even went out and took and few (faceoffs) and sat back down, and didn’t really seem to lose a beat.”The No. 4 Orange (9-2, 2-2 Atlantic Coast) used four faceoff men and three goalies en route to an 18-5 victory over the Statesmen (7-4, 4-0 Northeast). Desko said utilizing his team’s deep roster was a vote of confidence to him as Syracuse prepares to head into the ACC tournament next week.AdvertisementThis is placeholder textFor SU, it was Williams, Paduda, sophomore Joe DeMarco, senior Mike Iacono, junior Austin Wentworth and freshman Nate Farrell who took turns at the X. In the cage it was Wardwell for 38 minutes before giving way to junior transfer Warren Hill and then to third-year goalie Evan Molloy for almost nine minutes.Hill — who split time with Wardwell in SU’s loss at North Carolina on Saturday — saved five of Hobart’s shots on goal, smothering a couple of them at his shins on close-range low-angle shots. He allowed two goals to score in his time in the cage before Molloy was called upon.“We want to get all the goalies out there actually,” Desko said. “Warren, we’ve been very confident in all year long and I think Bobby proved his point out there tonight and on the scoreboard.”At the X, Williams has taken Syracuse’s faceoff unit to new heights this season and once again allowed the Orange to dominate time of possession.But as the Orange’s lead grew on Tuesday, the role turned into a rotation for Syracuse for the first time all season.Paduda was shelved last season with torn ligaments in his knuckles, and in his first dose of significant playing time went 6-for-9 at the X for SU. DeMarco managed to go 2-for-3 in his faceoff chances, Nate Farrell won his only one, Austin Wentworth was 0-for-1 and Iacono went 0-for-2.“Some of the younger guys have been working very hard and been a part of our scout group, doing things that are very important to the team,” Desko said. “It was nice they got to get on the field tonight in a game situation and show what they can do.” Comments Facebook Twitter Google+last_img read more


first_imgThe return of England striker Daniel Sturridge has been a key reason behind Liverpool’s impressive run of form, says manager Brendan Rodgers.Sturridge, 25, scored as his side defeated Crystal Palace 2-1 on Saturday to move into the FA Cup quarter-finals.The Reds have won four of the five games Sturridge has played in since he came back after nearly five months out because of calf and thigh injuries.”Daniel coming back has given us a big boost,” said Rodgers.”You can see his qualities – his speed, his touch and he doesn’t need too many chances to score.”The team is functioning at a high level.” Sturridge picked up a thigh injury while on international duty in September and then suffered setbacks as he injured his calf and thigh again before he made a goalscoring return in Liverpool’s 2-0 win over West Ham in January.At Selhurst Park, Liverpool fell behind to Fraizer Campbell’s 15th-minute goal, but Sturridge equalised before Adam Lallana grabbed the winner.The result means the Reds have only lost twice in 22 games since a 3-1 Premier League defeat against the Eagles in November.”Since that loss the players’ response has been magnificent and the character shown incredible,” added Rodgers.”It wasn’t a good feeling the last time we were at Selhurst Park. We were at a real low point with players trying to adapt to the expectations that had been put on them. “We had key players out so we had to get them playing with the intensity we have had over the last two years. That loss was a real adverse moment for us and from that the team has got better.”last_img read more